Prometic's Immune Globulin Intravenous 10% ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群1

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02269163
(ClinicalTrials.gov)
January 26, 201616/10/2014Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency DiseasesPrimary ImmunodeficiencyBiological: Immune Globulin Intravenous;Biological: Prometic's Immune Globulin Intravenous 10%Prometic Biotherapeutics, Inc.Atlantic Research GroupCompleted2 Years80 YearsAll82Phase 3United States